Moderna's Chief Medical Officer Jacqueline Miller, who led the development of the company's mRNA-based COVID-19 vaccine Spikevax, will step down effective March 2, the vaccine maker said on Friday. ...

CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Officer, beginning March 2, 2026. ...

Core Viewpoint - Recordati has entered into a collaboration and license agreement with Moderna to develop and commercialize mRNA-3927, an investigational product for treating propionic acidemia, leveraging Moderna's mRNA technology and Recordati's commercial infrastructure [1][6]. Group 1: Collaboration Details - The agreement allows Moderna to lead the development of mRNA-3927, while Recordati will handle global commercialization if the product is approved [1]. - Recordati will pay Moderna an upfront payment of USD 50 million, with potential additional payments of up to USD 110 million based on development and regulatory milestones [4]. - The transaction is subject to customary closing conditions, including U.S. antitrust clearance expected within 30 days [5]. Group 2: Product Information - mRNA-3927 aims to restore propionyl-CoA carboxylase (PCC) enzyme activity in patients with propionic acidemia, a rare inherited metabolic disorder characterized by toxic metabolite buildup [2][7]. - Interim clinical data published in Nature indicates early signs of clinical improvement, with a potential data readout expected by the end of 2026 [3][10]. - mRNA-3927 is designed as a targeted disease-modifying therapy and is currently in a registrational clinical study to reduce metabolic decompensation events [3][10]. Group 3: Market Context - Propionic acidemia affects approximately 1 in 100,000-150,000 individuals globally and currently lacks effective therapies targeting the disease's root cause [7]. - The collaboration aims to address the significant unmet medical need for disease-modifying treatment options in this patient population [6].

Core Viewpoint - Recordati has entered into a collaboration and license agreement with Moderna to develop and commercialize mRNA-3927, an investigational product for treating propionic acidemia, leveraging Moderna's mRNA technology and Recordati's commercial infrastructure [1][6]. Group 1: Collaboration Details - The agreement stipulates that Recordati will pay Moderna an upfront payment of USD 50 million, with potential additional payments of up to USD 110 million based on development and regulatory milestones [4]. - Recordati will lead global commercialization efforts if mRNA-3927 is approved, while Moderna will continue to lead its development [1][4]. Group 2: Product Overview - mRNA-3927 is designed to restore propionyl-CoA carboxylase (PCC) enzyme activity in patients with propionic acidemia, a rare inherited metabolic disorder characterized by toxic metabolite buildup [2][9]. - Interim clinical data published in Nature indicates early signs of clinical improvement, with a potential data readout expected by the end of 2026 [3][10]. Group 3: Market Context - Propionic acidemia affects approximately 1 in 100,000-150,000 individuals globally and currently lacks effective therapies targeting the underlying cause [7]. - If approved, mRNA-3927 could be the first disease-modifying treatment option available for this severe condition [2][6]. Group 4: Company Background - Recordati is an international pharmaceutical group with a focus on specialty and primary care, operating in around 150 countries and employing over 4,500 people [11]. - The company aims to address both common health challenges and rare diseases, emphasizing the belief that health is a fundamental right [11].

Core Viewpoint - Moderna has entered a strategic collaboration with Recordati to advance its investigational therapeutic mRNA-3927 for propionic acidemia through clinical development and global commercialization [1] Group 1: Collaboration Details - Moderna will lead the clinical development and manufacturing of mRNA-3927 [1] - The collaboration will provide Moderna with up to $160 million in upfront and near-term development and regulatory milestones [1] - Additional financial incentives include commercial and sales milestones, as well as tiered royalties on net sales [1] Group 2: Partner Information - Recordati is an international pharmaceutical group based in Milan, Italy [1] - The company specializes in treatments for specialty and primary care, as well as rare diseases, including propionic acidemia [1]

Core Viewpoint - Merck & Co., Inc. is recognized as a strong company with a solid growth potential, but its stock may struggle to distinguish itself in the pharmaceutical sector without clearer long-term growth indicators [2]. Group 1: Growth Projections - Merck has raised its revenue projections for new growth drivers to approximately $70 billion by the mid-2030s, indicating a strategic focus on expanding its product offerings [3]. - The company has increased its sales expectations for cardiometabolic and respiratory treatments to about $20 billion, up from a previous estimate of $15 billion [4]. - Merck has also significantly raised its forecast for infectious disease drugs, now anticipating around $15 billion in sales compared to an earlier estimate of $5 billion [4]. Group 2: Product Development and Trials - Merck and Moderna reported positive results from their experimental personalized cancer vaccine, which, when combined with Keytruda, reduced the risk of recurrence or death in high-risk melanoma patients by 49% after five years [5].

Company Overview - Moderna is a commercial-stage biotech founded in 2010, with its IPO in December 2018. The company's mRNA technology gained rapid validation through its COVID-19 vaccine, authorized in the U.S. in December 2020. As of August 2025, Moderna has 35 mRNA development candidates in clinical studies across various therapeutic areas, including infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases [8]. Market Sentiment - Recent options trading indicates a bearish sentiment among deep-pocketed investors towards Moderna, with 55% of notable options leaning bearish and only 33% bullish. This shift in sentiment is significant and suggests that market players should pay attention [1][2]. - The total options activity for Moderna has been extraordinary, with 12 put options totaling $1,840,896 and 6 call options amounting to $311,479 [2]. Price Targets and Trading Activity - Whales have been targeting a price range for Moderna between $30.0 and $50.0 over the last three months, based on the volume and open interest of options contracts [3]. - The average open interest for Moderna options is 531.31, with a total trading volume of 9,720.00. The trading activity has been concentrated within the strike price corridor of $30.0 to $50.0 over the past 30 days [4]. Recent Trading Data - Significant options trades include bearish put options with a total trade value of $1.1 million at a strike price of $42.00, and bullish put options valued at $300,000 with a strike price of $47.00. Additionally, there are neutral and bearish call options with varying trade values and strike prices [7]. Current Market Standing - As of the latest data, Moderna's trading volume is 3,713,575, with the stock price down by 2.71% at $47.39. Analysts have recently adjusted their ratings, with one expert from UBS revising the price target down to $34.0, indicating a neutral stance on the stock [10][11].

CAMBRIDGE, MA / ACCESS Newswire / January 26, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 13, 2026 to report its fourth quarter 2025 financial results, and provide a corporate update. ...

Investment Rating - The report maintains a "Buy" rating for the pharmaceutical and biotechnology industry, specifically highlighting companies such as Yuyuan Pharmaceutical and CanSino Biologics for potential investment opportunities [1]. Core Insights - The mRNA vaccine sector is experiencing significant advancements, with mRNA technology leading the shift towards efficient and personalized immunotherapy. This technology offers three main competitive advantages: rapid production capabilities, enhanced safety profiles, and flexibility in antigen design, which supports tailored treatments for cancer patients [1][4]. - The report identifies promising sub-sectors within the industry, ranking them as follows: innovative drugs, research services, CXO, traditional Chinese medicine, medical devices, and pharmacies. It suggests a focus on high-growth areas such as innovative drugs, particularly in small nucleic acid therapies, and high-dividend sectors like traditional Chinese medicine and pharmacies [10][11]. Summary by Sections Market Performance - The A-share pharmaceutical index has shown a year-to-date increase of 6.66%, outperforming the CSI 300 index by 5.10%. The Hang Seng Biotechnology Index has also seen a year-to-date rise of 12.40% [4][9]. - Notable performers in the market include *ST Changyao (+70.37%) and Hualan Biological (+32.21%) for the week, while the worst performers include Kain Technology (-13.83%) and Aidi Pharmaceutical (-13.70%) [9]. Clinical Developments - Corcept Therapeutics has reported positive results from its Phase III trial for relacorilant, which shows survival benefits for patients with platinum-resistant ovarian cancer. Additionally, Maiwei Biologics has initiated its first patient dosing in the U.S. for its CDH17-ADC innovative drug targeting advanced colorectal and gastrointestinal tumors [4]. Investment Recommendations - Specific companies to watch include: - From the PD1 PLUS perspective: 3SBio, Kanyin Biologics, Innovent Biologics, and Zai Lab [11]. - From the ADC perspective: InnoCare Pharma, Kelun-Biotech, and Baillie Gifford [11]. - From the small nucleic acid perspective: Frontier Biotechnologies, Fuyuan Pharmaceutical, and Yuyuan Pharmaceutical [11]. - From the self-immune perspective: Kangnuo Pharmaceutical, Yifang Biologics, and Yipinhong [11]. - From the innovative drug leaders: BeiGene and HengRui Medicine [11]. - From the CXO and upstream research services: WuXi AppTec, Haoyuan Pharmaceutical, and Aopumai [11]. - From the medical device sector: United Imaging Healthcare and Yuyue Medical [11].

Investment Rating - The report maintains a "Cautious" investment rating for the pharmaceutical sector, highlighting the need to focus on specific investment opportunities within the CXO segment and AI pharmaceutical developments [2]. Core Insights - The pharmaceutical sector is currently experiencing a mixed performance, with the Shenwan Pharmaceutical and Biological Index down by 0.4% this week, ranking 27th among 31 Shenwan primary sub-industries [3][5]. - The overall valuation of the pharmaceutical sector stands at 30.3 times earnings, placing it 12th among 31 Shenwan primary industries [5]. - The report emphasizes the ongoing transformation of the pharmaceutical retail industry towards comprehensive health services, driven by a joint opinion from nine government departments [13][14]. - New drug development remains active, with significant advancements such as the NDA acceptance for Bai Li Tianheng's EGFR×HER3 dual antibody ADC and Moderna's personalized mRNA cancer vaccine showing promising results [15][16]. Market Performance - The Shenwan Pharmaceutical and Biological Index decreased by 0.4%, while the Shanghai Composite Index increased by 0.84% [3]. - Among the secondary sectors, the performance varied, with raw materials (+2.4%) and offline pharmacies (+9.7%) showing positive growth, while medical research outsourcing (-4.0%) and chemical preparations (-1.7%) faced declines [5][12]. Industry Dynamics - By the end of 2025, China's total population is projected to be approximately 1.40489 billion, with a birth rate of 7.92 million, indicating a slight decrease in population compared to the previous year [12]. - The pharmaceutical retail industry is undergoing a critical transformation, with a focus on enhancing pharmacy services and optimizing industry structure [13][14]. - The report outlines five key measures to promote high-quality development in the pharmaceutical retail sector, including improving pharmacy service capabilities and enhancing emergency service functions [14]. Company Developments - Bai Li Tianheng's NDA for the EGFR×HER3 dual antibody ADC has been accepted, targeting esophageal squamous cell carcinoma [15]. - Moderna's personalized mRNA cancer vaccine has shown a 49% reduction in recurrence or death risk compared to monotherapy with Keytruda [16]. - The launch of Insilico Medicine's large language model training framework aims to enhance drug discovery capabilities significantly [16]. Financing Dynamics - OpenEvidence, an AI medical platform, successfully raised $250 million in Series D funding, achieving a post-money valuation of $12 billion [22]. - Qixing Pharmaceuticals completed a $287 million D1 round of financing to advance its clinical pipeline for cardiovascular and metabolic diseases [22]. Performance Forecasts - Several companies in the pharmaceutical sector have released optimistic earnings forecasts for 2025, indicating a clear industry trend [2]. - Notable companies to watch include WuXi AppTec, Kanglong Chemical, and Tigermed, among others, as they are expected to benefit from the ongoing industry developments [2].